The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

10.18632/oncotarget.1925

Saved in:

Bibliographic Details
Main Authors:	Ko T.K., Chuah C.T., Huang J.W., Ng K.-P., Ong S.T.
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	2020
Subjects:	BCR ABL protein BH3 protein imatinib navitoclax protein bcl 2 protein bcl xl protein tyrosine kinase inhibitor venetoclax 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide aniline derivative antineoplastic agent benzamide derivative fused heterocyclic rings piperazine derivative protein kinase inhibitor pyrimidine derivative sulfonamide Article blood toxicity cell death chronic myeloid leukemia drug activity human human cell IC50 maximum tolerated dose protein expression thrombocyte lifespan thrombocytopenia antagonists and inhibitors apoptosis cancer stem cell drug effects drug resistance drug screening Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism tumor cell line Aniline Compounds Antineoplastic Agents Apoptosis Benzamides Bicyclo Compounds, Heterocyclic Cell Line, Tumor Drug Resistance, Neoplasm Humans Imatinib Mesylate Neoplastic Stem Cells Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-bcl-2 Pyrimidines Sulfonamides Tumor Stem Cell Assay
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/174163
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-174163
record_format	dspace
spelling	sg-nus-scholar.10635-1741632023-09-20T08:53:03Z The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors Ko T.K. Chuah C.T. Huang J.W. Ng K.-P. Ong S.T. CANCER SCIENCE INSTITUTE OF SINGAPORE DUKE-NUS MEDICAL SCHOOL BCR ABL protein BH3 protein imatinib navitoclax protein bcl 2 protein bcl xl protein tyrosine kinase inhibitor venetoclax 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide aniline derivative antineoplastic agent benzamide derivative fused heterocyclic rings imatinib navitoclax piperazine derivative protein bcl 2 protein kinase inhibitor pyrimidine derivative sulfonamide Article blood toxicity cell death chronic myeloid leukemia drug activity human human cell IC50 maximum tolerated dose protein expression thrombocyte lifespan thrombocytopenia antagonists and inhibitors apoptosis cancer stem cell drug effects drug resistance drug screening Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism tumor cell line Aniline Compounds Antineoplastic Agents Apoptosis Benzamides Bicyclo Compounds, Heterocyclic Cell Line, Tumor Drug Resistance, Neoplasm Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplastic Stem Cells Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-bcl-2 Pyrimidines Sulfonamides Tumor Stem Cell Assay 10.18632/oncotarget.1925 Oncotarget 5 19 9033-9038 2020-09-03T10:41:23Z 2020-09-03T10:41:23Z 2014 Article Ko T.K., Chuah C.T., Huang J.W., Ng K.-P., Ong S.T. (2014). The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 5 (19) : 9033-9038. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.1925 19492553 https://scholarbank.nus.edu.sg/handle/10635/174163 Unpaywall 20200831
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	BCR ABL protein BH3 protein imatinib navitoclax protein bcl 2 protein bcl xl protein tyrosine kinase inhibitor venetoclax 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide aniline derivative antineoplastic agent benzamide derivative fused heterocyclic rings imatinib navitoclax piperazine derivative protein bcl 2 protein kinase inhibitor pyrimidine derivative sulfonamide Article blood toxicity cell death chronic myeloid leukemia drug activity human human cell IC50 maximum tolerated dose protein expression thrombocyte lifespan thrombocytopenia antagonists and inhibitors apoptosis cancer stem cell drug effects drug resistance drug screening Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism tumor cell line Aniline Compounds Antineoplastic Agents Apoptosis Benzamides Bicyclo Compounds, Heterocyclic Cell Line, Tumor Drug Resistance, Neoplasm Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplastic Stem Cells Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-bcl-2 Pyrimidines Sulfonamides Tumor Stem Cell Assay
spellingShingle	BCR ABL protein BH3 protein imatinib navitoclax protein bcl 2 protein bcl xl protein tyrosine kinase inhibitor venetoclax 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide aniline derivative antineoplastic agent benzamide derivative fused heterocyclic rings imatinib navitoclax piperazine derivative protein bcl 2 protein kinase inhibitor pyrimidine derivative sulfonamide Article blood toxicity cell death chronic myeloid leukemia drug activity human human cell IC50 maximum tolerated dose protein expression thrombocyte lifespan thrombocytopenia antagonists and inhibitors apoptosis cancer stem cell drug effects drug resistance drug screening Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism tumor cell line Aniline Compounds Antineoplastic Agents Apoptosis Benzamides Bicyclo Compounds, Heterocyclic Cell Line, Tumor Drug Resistance, Neoplasm Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplastic Stem Cells Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-bcl-2 Pyrimidines Sulfonamides Tumor Stem Cell Assay Ko T.K. Chuah C.T. Huang J.W. Ng K.-P. Ong S.T. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
description	10.18632/oncotarget.1925
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Ko T.K. Chuah C.T. Huang J.W. Ng K.-P. Ong S.T.
format	Article
author	Ko T.K. Chuah C.T. Huang J.W. Ng K.-P. Ong S.T.
author_sort	Ko T.K.
title	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
title_short	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
title_full	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
title_fullStr	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
title_full_unstemmed	The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
title_sort	bcl2 inhibitor abt-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/174163
_version_	1778169709692190720

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

Similar Items